Document type
ArticleVersion
Published versionPublication date
Publication license
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/187024
Vericiguat en insuficiencia cardíaca: de la evidencia científica a la práctica clínica
Journal Title
Director/Tutor
Journal ISSN
Volume Title
Related resource
Abstract
Despite currently available treatments, risk of death and hospitalizations in patients with heart failure with reduced ejection fraction (HFrEF) remains high. The pathophysiology of HFrEF includes neurohormonal activation characterized by stimulation of deleterious pathways (i.e., sympathetic nervous and renin-angiotensin-aldosterone systems) and suppression of pro-tective pathways such as nitric oxide-dependent pathways. Inhibition or stimulation of some, but not all, of these pathways is insufficient. In HFrEF, there is reduced nitric oxide, soluble guanylate cyclase, and cGMP activity, leading to deleterious effects in the myocardial, vascu-lar, and renal systems. Vericiguat is able to stimulate the activity of this protective pathway. The VICTORIA study demonstrated that the addition of vericiguat to optimal medical treatment in patients with HFrEF and recent decompensation significantly reduced the incidence of the primary endpoint, a composite of cardiovascular death or HF hospitalization, with a number needed to treat of 24 patients and excellent tolerability.
Subject (English)
Citation
Citation
GONZÁLEZ-JUANATEY, J. R., et al. Vericiguat en insuficiencia cardíaca: de la evidencia científica a la práctica clínica. Revista Clínica Española. 2022. Vol. 222, num. 6, pags. 359-369. ISSN 2254-8874. [consulted: 8 of August of 2026]. Available at: https://hdl.handle.net/2445/187024